Evidence map›Paper›PMID 33883922›Full record

ArticleJournal of inflammation research2021

Integrated Systems Pharmacology and Surface Plasmon Resonance Approaches to Reveal the Synergistic Effect of Multiple Components of Gu-Ben-Ke-Chuan Decoction on Chronic Bronchitis.

Zhiqiang Luo, Guohua Yu, Wubin Wang, Rui Sun, Binbin Zhang, Jing Wang, Jing Liu, Shan Gao, Peng Wang, Yuanyuan Shi

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zhiqiang Luo *School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Guohua Yu *School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Wubin Wang *School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Rui SunSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Binbin ZhangSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Jing WangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People's Republic of China.
Jing LiuSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Shan GaoSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Peng WangThe First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, People's Republic of China.
Yuanyuan ShiSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Beijing University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGu-Ben-Ke-Chuan (GBKC) decoction, a well-known prescription composed of seven herbs, has been widely used for treating chronic bronchitis (CB). However, the pharmacological constituents of GBKC and the underlying mechanisms by which these components act on CB remain unclear.

methodsUltra-high-pressure liquid chromatography coupled with linear ion trap-Orbitrap tandem mass spectrometry (UHPLC-LTQ-Orbitrap) was first employed to rapidly identify compounds from GBKC. Thereafter, network pharmacology and molecular docking analyses were performed to identify the potential active constituents, candidate targets, and major pathways. Finally, the affinities between the key compounds and targets were verified via surface plasmon resonance (SPR) analysis. In addition, the anti-inflammatory effect of GBKC was verified using an LPS-induced inflammatory cell model based on the predicted results.

resultsA total of 53 major compounds were identified in the GBKC decoction. After network pharmacology-based virtual screening, 141 major targets and 39 main compounds were identified to be effective in the treatment of CB. The major targets were highly enriched in the tumor necrosis factor (TNF) signaling pathway, suggesting that GBKC could attenuate the inflammatory response in patients with CB. Furthermore, molecular docking results indicated that 20 pairs of components and target proteins relevant to the TNF pathway exhibited notable interactions. Among them, eight compound-target pairs exhibited good affinity as per SPR analysis. In addition, the production of interleukin 6 and TNF-α in LPS-induced MH-S cells was suppressed after GBKC treatment.

conclusionThis study successfully clarified the mechanism of action of GBKC against CB, which demonstrated that the integrated strategy described above is reliable for identifying the active compounds and mechanisms responsible for the pharmacological activities of GBKC decoction.

Indexed as

chronic bronchitisGu-Ben-Ke-Chuan decoctionnetwork pharmacologysurface plasmon resonanceUHPLC-LTQ-Orbitrap

Identifiers

PMID33883922
PMCPMC8055291
OpenAlexW3197170049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.